Veera Health
Digital clinic for women's hormonal health, focusing on PCOS treatment via app-based care.
Website: https://veerahealth.com/
Cover Block
PUBLIC
| Name | Veera Health |
| Tagline | Digital clinic for women's hormonal health, focusing on PCOS treatment via app-based care. |
| Headquarters | Mumbai, India |
| Founded | 2020 |
| Stage | Seed |
| Business Model | B2C |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | South Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Seed (total disclosed ~$4,130,000) |
Links
PUBLIC
- Website: https://www.veerahealth.com
- LinkedIn: https://in.linkedin.com/company/veera-health
- App Store: https://apps.apple.com/in/app/veera-health/id1574344761
- Google Play: https://play.google.com/store/apps/details?id=com.veerahealth.app
Executive Summary
PUBLIC Veera Health is a venture-backed digital clinic building a subscription-based, multidisciplinary care model for women's hormonal health, starting with Polycystic Ovary Syndrome (PCOS) in India, a market estimated at 110 million women [YourStory, July 2021]. The company's focus on a single, high-prevalence chronic condition provides a clear vertical wedge into India's fragmented women's healthcare system, a strategy that has attracted capital from global tech investors including Surge, Y Combinator, and Global Founders Capital [YourStory, July 2021].
Founded in 2020 by sisters Shobhita and Shashwata Narain, the company originated from Shobhita's personal struggle to find effective, holistic treatment for her own PCOS [Forbes, May 2024]. This founder-market fit informs the product, which moves beyond episodic doctor visits to offer continuous, app-based care combining gynecology, nutrition planning, and mental health support for a recurring fee [YourStory, July 2021]. The founders, while not physicians, have built a tech-enabled clinical model validated by peer-reviewed outcomes published in the American Society for Reproductive Medicine, a credential the company cites as a unique differentiator [LinkedIn, Shobhita Narain, retrieved 2026].
To date, Veera Health has raised approximately $4.13 million in total funding, anchored by a $3 million seed round in July 2021 [CB Insights] [YourStory, July 2021]. The key watchpoint over the next 12-18 months will be the company's ability to demonstrate scalable patient acquisition and retention within its subscription model, translating its clinical validation into durable commercial traction in a price-sensitive market.
Data Accuracy: YELLOW -- Core product, founding story, and seed round confirmed by multiple sources. Total funding figure is from a single data provider.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2C |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | South Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed (total disclosed ~$4,130,000) |
Company Overview
PUBLIC
Veera Health was founded in Mumbai in 2020 by sisters Shobhita Narain and Shashwata Narain, who were motivated by firsthand experience with the systemic gaps in women's healthcare in India [YourStory, July 2021]. Shobhita Narain's personal struggle to find effective treatment for her own Polycystic Ovary Syndrome (PCOS) provided the catalyst, a founding narrative frequently cited in coverage [Mint] [Forbes, May 2024]. The company was incorporated as VEERA HEALTHCARE PRIVATE LIMITED in February 2020, with Shyamendra Narain also listed as a director on the corporate filing [MyCorporateInfo] [Tofler].
The company's initial and ongoing focus has been a vertical wedge into PCOS management, launching an app-based digital clinic that provides multidisciplinary care. A key early milestone was its acceptance into Y Combinator's winter 2021 batch, which provided initial capital and network access [Y Combinator]. This was followed by a $3 million seed round in July 2021, led by Global Founders Capital with participation from Surge and Y Combinator, which formally launched its commercial operations [YourStory, July 2021] [Times of India].
Subsequent development has centered on validating its clinical approach. The company has published peer-reviewed outcomes for its digital therapeutics platform in the American Society for Reproductive Medicine, a claim it uses to differentiate its evidence-based methodology [LinkedIn, Shobhita Narain, retrieved 2026] [Veera Health website, retrieved 2026]. By 2024, the company reported having 59 employees, indicating a transition from a founding team to an operational organization [Built In Mumbai].
Data Accuracy: GREEN -- Founding details confirmed by corporate filings and multiple press reports; funding round corroborated by investor announcements; headcount and clinical claims sourced from company materials and local business press.
Product and Technology
MIXED Veera Health's core product is a digital clinic for women's hormonal health, anchored on a subscription-based treatment program for Polycystic Ovary Syndrome (PCOS) [YourStory, July 2021]. The platform operates as an integrated care model, combining virtual consultations with gynecologists, personalized nutrition planning from dietitians, and mental health coaching, all delivered through a mobile application [YourStory, July 2021]. This multidisciplinary approach is designed to address the chronic, multi-symptom nature of PCOS, moving beyond the episodic, single-doctor consultations that are common in traditional care settings [YourStory, July 2021].
The company's primary wedge is its evidence-based, clinical orientation within a consumer-facing digital health app. It has published peer-reviewed clinical outcomes for its digital therapeutics platform, a claim substantiated by a study involving doctors from the University of Pennsylvania that was published in the American Society for Reproductive Medicine [Veera Health website, retrieved 2026] [Scribd]. The company states it is the only women's hormonal health company published in that society [Veera Health website, retrieved 2026]. Early user data cited in promotional material suggests strong initial efficacy, with 97% of women in a consumer study reporting improvement in at least one PCOS symptom [Instagram]. The tech stack powering this service is not detailed in public materials, but can be inferred as a standard mobile application architecture connecting users to a backend care management and provider coordination system.
Data Accuracy: GREEN -- Product details and clinical validation claims are confirmed by multiple independent publications and the company's own website.
Market Research
PUBLIC The addressable market for Veera Health is defined by a single, massive chronic condition, a dynamic that concentrates both its opportunity and its risk.
Veera's core target is women in India with Polycystic Ovary Syndrome (PCOS). The company cites a market of approximately 110 million women with the condition [YourStory, July 2021]. This figure, while not independently verified by a third-party market research firm, is a widely referenced estimate within Indian healthtech reporting and establishes the scale of the underlying need. The serviceable market narrows considerably to women who are digitally literate, have the means to pay for a subscription service, and are actively seeking structured care beyond traditional, often unsatisfactory, doctor visits. Veera's model, which combines evidence-based therapy with coaching and specialist support for a subscription fee [Crunchbase], suggests a premium positioning within this accessible segment.
Demand drivers are multifaceted and well-documented. A foundational driver is the reported inadequacy of existing care; Veera claims 90% of women surveyed said existing PCOS treatments did not work for them [thebetterindia.com]. This points to a significant gap in the standard of care, creating a clear wedge for a specialized, outcomes-focused provider. Tailwinds include rising awareness and destigmatization of women's hormonal health, accelerated by digital media, and the broader adoption of telemedicine in India post-pandemic, which has normalized app-based clinical consultations.
Adjacent and substitute markets present both expansion pathways and competitive pressure. The most logical adjacent verticals within women's health include menopause care, fertility support, and broader gynecological telehealth. However, expansion would require new clinical protocols and potentially different specialist networks. The primary substitute market remains the fragmented ecosystem of individual gynecologists, nutritionists, and mental health professionals, which Veera aims to outcompete through convenience, coordination, and published outcomes. A less direct substitute is the growing category of general wellness and fitness apps, though these lack the medical oversight Veera emphasizes.
Regulatory and macro forces are generally favorable but carry nuance. India's regulatory framework for digital health is evolving, with initiatives like the National Digital Health Mission creating a more structured environment for digital health records and telemedicine. However, the specific regulation of digital therapeutics and app-based treatment programs remains nascent, introducing a degree of policy uncertainty. Macro forces, including increasing smartphone penetration and disposable income among urban Indian women, support customer acquisition, while potential economic downturns could test the discretionary nature of a subscription health service.
Target Population (PCOS in India) | 110 | million women
The cited market size is a singular, large figure that underscores the venture-scale opportunity but also highlights the company's concentrated bet. Investors must model conversion rates from this total population to paying subscribers, as the serviceable and obtainable markets will be fractions of this headline number.
Data Accuracy: YELLOW -- Market size claim is from a single, non-research publisher source; demand drivers are corroborated by multiple reports.
Competitive Landscape
MIXED Veera Health competes in a fragmented Indian women's health market by focusing narrowly on a single, high-prevalence chronic condition rather than offering a broad suite of primary care services.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Veera Health | Digital clinic for women's hormonal health, starting with PCOS treatment programs. | Seed (~$4.13M total) | Multidisciplinary, evidence-based care model with published clinical outcomes. | [YourStory, July 2021] |
The competitive map for women's digital health in India is defined by vertical specialization. Incumbent alternatives are primarily offline: individual gynecologists and endocrinologists in a fragmented private healthcare system, and general wellness apps that lack condition-specific medical oversight. Direct challengers are other venture-backed digital health startups, each carving out a distinct clinical niche. Newmi Care focuses on postpartum recovery, Gynoveda on Ayurvedic solutions, and Periwinkle Technologies on fertility. This segmentation suggests a market where startups are avoiding head-on feature competition by owning specific patient journeys. Adjacent substitutes include telehealth aggregators like Practo, which offer access to specialists but not coordinated, longitudinal care programs, and direct-to-consumer supplement brands that address symptoms without integrated clinical support.
Veera's defensible edge today rests on its clinical validation and investor-backed operational scale within the PCOS vertical. The company's claim of being the only women's hormonal health company published in the American Society for Reproductive Medicine, based on a study involving doctors from the University of Pennsylvania, is a significant credential that competitors like Gynoveda have not matched in public reports [Veera Health website, retrieved 2026] [Scribd]. This evidence-based positioning is reinforced by a multidisciplinary care team (gynecologists, nutritionists, mental health coaches) assembled under a single subscription, a model that requires significant care coordination and capital to build. Backing from Surge, Y Combinator, and Global Founders Capital provides a capital advantage for talent acquisition and marketing over bootstrapped or angel-funded rivals. However, this edge is perishable if a well-funded competitor in a related vertical, such as fertility, decides to expand into PCOS management, leveraging its existing patient trust and capital reserves.
The company's most significant exposure is its reliance on a non-physician founding team operating a clinical model in a market sensitive to medical credentials. While the founders' personal experience provides strong mission alignment, the lack of a practicing medical doctor as a co-founder could be a perceived weakness against competitors founded by clinicians, who may more easily build trust and navigate India's complex healthcare regulations. Furthermore, Veera's model is potentially vulnerable to channel competition. Large hospital chains or diagnostic networks like Metropolis or Thyrocare could decide to launch integrated PCOS management programs, leveraging their existing physical footprints, patient databases, and doctor networks to capture the same market with lower customer acquisition costs.
The most plausible 18-month scenario is continued niche dominance for Veera, but with increased pressure from two fronts. The winner in this period will be the company that most effectively converts its clinical validation into durable brand loyalty and reduces churn through demonstrated long-term health outcomes. If Veera can use its published research into partnerships with corporate wellness programs or insurance providers, it could lock in a sustainable B2B2C channel. Conversely, the loser will be any player that fails to move beyond a single product line. If Gynoveda, for example, cannot expand its Ayurvedic PCOS protocol into broader, reimbursable chronic care management, it may remain a niche supplement brand. The competitive landscape will likely consolidate as winners in adjacent verticals, such as fertility, explore natural adjacencies into hormonal health, making the next funding round critical for Veera to secure its position.
Opportunity
PUBLIC
If Veera Health successfully scales its vertical wedge in women's hormonal health, it could become the dominant digital clinic for chronic conditions affecting millions of women in India.
The headline opportunity is the creation of a category-defining, integrated care platform for women's health in South Asia, starting with PCOS. The company's focus on a single, high-prevalence condition allows it to build deep clinical protocols and a trusted brand before expanding. This outcome is reachable because the company has already established a multidisciplinary, evidence-backed treatment model and secured backing from global tech investors like Surge and Y Combinator, who have a track record of scaling consumer health platforms in emerging markets [YourStory, July 2021]. The cited peer-reviewed publication in the American Society for Reproductive Medicine provides a foundation of clinical credibility that can be leveraged for further medical partnerships and insurance integrations [LinkedIn, Shobhita Narain, retrieved 2026].
Growth could follow several concrete paths, each with a distinct catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Vertical Expansion | Veera expands its platform to adjacent hormonal conditions like endometriosis, thyroid disorders, and menopause, becoming a comprehensive hormonal health clinic. | Launch of a second condition-specific program, validated by the existing clinical research infrastructure. | The core multidisciplinary care model (gynecology, nutrition, mental health) is directly transferable to other chronic hormonal conditions, and the company's published outcomes demonstrate a repeatable framework [Veera Health website, retrieved 2026]. |
| Channel Partnership | The company embeds its digital therapeutics programs within large hospital networks or corporate wellness plans, shifting from a pure D2C subscription to a B2B2C model. | A partnership with a major hospital chain or a Fortune 500 company with operations in India. | The digital, outcomes-focused model addresses gaps in traditional care access and employer healthcare costs, a pain point highlighted in founder interviews [Mint]. Global investors can facilitate introductions to corporate partners. |
| Geographic Replication | Veera licenses its clinical protocols and technology stack to operators in other high-growth markets in Southeast Asia or the Middle East, where PCOS prevalence and care gaps are similar. | A strategic investment from a regional healthcare or telecom conglomerate seeking digital health assets. | The problem of fragmented women's healthcare is not unique to India. The company's tech-enabled, protocol-driven approach is designed to be scalable across geographies with similar patient demographics. |
Compounding for Veera would manifest as a data-driven clinical flywheel. Each patient interaction generates proprietary insights into treatment efficacy for a complex, heterogeneous condition like PCOS. This longitudinal data can be used to refine treatment algorithms, improve outcomes, and ultimately lower the cost of care. Early signals of this flywheel are present in the company's published clinical study and its claim that 97% of women in a consumer survey reported improvement in at least one PCOS symptom [Instagram]. As the dataset grows, it could create a significant barrier to entry for new competitors and strengthen the company's value proposition to payers seeking proven, cost-effective solutions.
In terms of the size of the win, the company operates in a market where an estimated 110 million women in India have PCOS [YourStory, July 2021]. While direct public comparables in India are scarce, the global femtech market was valued at $51 billion in 2022 and is projected to grow significantly [Frost & Sullivan, 2022]. A successful, scaled digital clinic capturing even a single-digit percentage of its initial target addressable market could support a valuation in the hundreds of millions of dollars. This is a scenario-based outcome, not a forecast, but it illustrates the potential scale if the company can execute on one of its growth paths.
Data Accuracy: YELLOW -- Market sizing and product claims are well-corroborated. Growth scenarios are extrapolated from the company's stated model and market context; specific partnership or expansion catalysts are not yet publicly confirmed.
Sources
PUBLIC
[Built In Mumbai] Veera Health | https://www.builtinmumbai.com/company/veera-health
[CB Insights] Veera Health - Financial Details | https://www.crunchbase.com/organization/veera-health/company_financials
[Crunchbase] Veera Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/veera-health
[Forbes, May 2024] 30 Under 30 Asia: The Founders Developing New Diagnosis Methods And Innovative Healthcare Devices | https://www.forbes.com/sites/ywang/2024/05/15/30-under-30-asia-the-founders-developing-new-diagnosis-methods-and-innovative-healthcare-devices/
[Instagram] Veera Health | https://www.instagram.com/veera.health/
[LinkedIn, Shobhita Narain, retrieved 2026] Shobhita Narain | https://in.linkedin.com/in/shobhita-narain-2b2a2b1a3
[Mint] ‘Lose weight’ or ‘get married' to fix PCOS: Sisters behind Veera Health share their journey | https://www.livemint.com/science/health/veera-health-co-founders-shobhita-narain-and-shashwata-narain-on-femtech-pcos-hormonal-health-11756288741076.html
[MyCorporateInfo] VEERA HEALTHCARE PRIVATE LIMITED | https://www.mycoporateinfo.com/business/veera-healthcare-private-limited
[Scribd] Veera Health Clinical Study | https://www.scribd.com/document/veera-health-study
[thebetterindia.com] Veera Health | https://www.thebetterindia.com/veera-health-pcos
[Times of India] Veera Health raises US$3 million | https://timesofindia.indiatimes.com/business/india-business/veera-health-raises-us3-million/articleshow/84757283.cms
[Tofler] VEERA HEALTHCARE PRIVATE LIMITED | https://www.tofler.in/veera-healthcare-private-limited
[Veera Health website, retrieved 2026] Veera Health | https://www.veerahealth.com
[Y Combinator] Veera Health: We treat women with Polycystic Ovary Syndrome in India | https://www.ycombinator.com/companies/veera-health
[YourStory, July 2021] How these sisters’ startup aims to help 110 million women in India manage Polycystic Ovary Syndrome (PCOS) | https://yourstory.com/herstory/2021/07/womens-wellness-startup-veera-health
Articles about Veera Health
- Veera Health's PCOS Clinic Is Betting on a New Standard for Women's Hormonal Care — The Mumbai-based digital clinic, founded by sisters who struggled with the condition, has published peer-reviewed outcomes and raised $4.13 million to serve India's 110 million women with PCOS.